» Articles » PMID: 31571650

Therapeutic Potential of Natural Compounds from Chinese Medicine in Acute and Subacute Phases of Ischemic Stroke

Overview
Date 2019 Oct 2
PMID 31571650
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Stroke is one of the leading causes of death and disability in adults worldwide, resulting in huge social and financial burdens. Extracts from herbs, especially those used in Chinese medicine, have emerged as new pharmaceuticals for stroke treatment. Here we review the evidence from preclinical studies investigating neuroprotective properties of Chinese medicinal compounds through their application in acute and subacute phases of ischemic stroke, and highlight potential mechanisms underlying their therapeutic effects. It is noteworthy that many herbal compounds have been shown to target multiple mechanisms and in combinations may exert synergistic effects on signaling pathways, thereby attenuating multiple aspects of ischemic pathology. We conclude the paper with a general discussion of the prospects for novel natural compound-based regimens against stroke.

Citing Articles

Pharmacodynamic advantages and characteristics of traditional Chinese medicine in prevention and treatment of ischemic stroke.

Zhang H, Jin B, You X, Yi P, Guo H, Niu L Chin Herb Med. 2023; 15(4):496-508.

PMID: 38094018 PMC: 10715896. DOI: 10.1016/j.chmed.2023.09.003.


The Implications of Microglial Regulation in Neuroplasticity-Dependent Stroke Recovery.

Qiao C, Liu Z, Qie S Biomolecules. 2023; 13(3).

PMID: 36979506 PMC: 10046452. DOI: 10.3390/biom13030571.


A Review on Therapeutic Potential of Natural Phytocompounds for Stroke.

Almutairi F, Ullah A, Althobaiti Y, Irfan H, Shareef U, Usman H Biomedicines. 2022; 10(10).

PMID: 36289828 PMC: 9599280. DOI: 10.3390/biomedicines10102566.


Insights into the Explicit Protective Activity of Herbals in Management of Neurodegenerative and Cerebrovascular Disorders.

Behl T, Makkar R, Sehgal A, Sharma N, Singh S, Albratty M Molecules. 2022; 27(15).

PMID: 35956919 PMC: 9370592. DOI: 10.3390/molecules27154970.


Exploring Active Compounds and Mechanisms of Angong Niuhuang Wan on Ischemic Stroke Based on Network Pharmacology and Molecular Docking.

Zhang Y, Liu X, Long J, Cheng X, Wang X, Feng X Evid Based Complement Alternat Med. 2022; 2022:2443615.

PMID: 35388303 PMC: 8977296. DOI: 10.1155/2022/2443615.


References
1.
Weinberger J . Evolving therapeutic approaches to treating acute ischemic stroke. J Neurol Sci. 2006; 249(2):101-9. DOI: 10.1016/j.jns.2006.06.010. View

2.
Dirnagl U, Iadecola C, Moskowitz M . Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22(9):391-7. DOI: 10.1016/s0166-2236(99)01401-0. View

3.
Liang Q, Wu Q, Jiang J, Duan J, Wang C, Smith M . Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011; 286(30):26470-9. PMC: 3143611. DOI: 10.1074/jbc.M111.227934. View

4.
Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View

5.
Akpan N, Troy C . Caspase inhibitors: prospective therapies for stroke. Neuroscientist. 2012; 19(2):129-36. PMC: 9214550. DOI: 10.1177/1073858412447875. View